Liu Yi, Wang Ding, Zhao Kui-Ling, Zhu Jian-Wei, Yin Hai-Bing, Wei Ying-Ze, Wu Zhi-Jun, Cheng Guo-Jian, Wang Feng, Ni Feng, Wang Xiao-Lin, Cao Guang-Xin, Huang Jian, Cai Jing
Department of Radiotherapy, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China.
Tumour Biol. 2014 Jul;35(7):6351-6. doi: 10.1007/s13277-014-1839-7. Epub 2014 Mar 25.
In this study, the expression of neural precursor cell expressed developmentally downregulated 9 (NEDD9) in benign and malignant gastric tissues was investigated, and the significance of NEDD9 in gastric cancer prognosis was explored. Immunohistochemistry was used to detect NEDD9 expression in gastric cancer, nontumor gastric, and normal gastric tissues. The relationship between NEDD9 expression in gastric cancer tissues and the clinicopathologic factors was examined using the Mann-Whitney U test. The two factors between NEDD9 expression and tumor node metastasis (TNM) stage in gastric cancer patients were analyzed by Spearman rank correlation analysis. The Kaplan-Meier method and log-rank test were used to compare the overall survival of NEDD9 negative, weak positive expression, and strong positive expression group. NEDD9 expression rates were significantly higher (P < 0.001) in gastric cancer tissues (162 out of 187, 86.6 %) compared with normal (2 out of 11, 18.2 %) and nontumor (11 out of 58, 19.0 %) gastric tissues. The upregulated NEDD9 expression in gastric cancer tissue was significantly correlated with high preoperative CEA level (P = 0.044), poor differentiation (P = 0.007), tissue invasion (P = 0.015), present lymph node metastasis (P < 0.001), and high TNM stage (P < 0.001). NEDD9 expression was positively correlated with clinical TNM stage. Advancing clinical TNM stage corresponded with higher NEDD9 expression (r s = 0.289, P < 0.001). The overall 5-year survival of gastric cancer patients with strong positive NEDD9 expression was significantly shorter compared with the survival of NEDD9 negative and weakly positive expression group. NEDD9 may be used as a biomarker in the clinical setting to predict the prognosis of gastric cancer patients.
在本研究中，调查了神经前体细胞表达发育下调基因9（NEDD9）在胃良恶性组织中的表达情况，并探讨了NEDD9在胃癌预后中的意义。采用免疫组织化学法检测NEDD9在胃癌、非肿瘤胃组织及正常胃组织中的表达。使用Mann-Whitney U检验分析胃癌组织中NEDD9表达与临床病理因素之间的关系。采用Spearman等级相关分析对胃癌患者中NEDD9表达与肿瘤淋巴结转移（TNM）分期这两个因素进行分析。采用Kaplan-Meier法和对数秩检验比较NEDD9阴性、弱阳性表达和强阳性表达组的总生存率。与正常胃组织（11例中的2例，18.2%）和非肿瘤胃组织（58例中的11例，19.0%）相比，胃癌组织中NEDD9表达率显著更高（P < 0.001，187例中的162例，86.6%）。胃癌组织中NEDD9表达上调与术前癌胚抗原（CEA）水平高（P = 0.044）、低分化（P = 0.007）、组织浸润（P = 0.015）、存在淋巴结转移（P < 0.001）及高TNM分期（P < 0.001）显著相关。NEDD9表达与临床TNM分期呈正相关。临床TNM分期进展与更高的NEDD9表达相对应（rs = 0.289，P < 0.001）。NEDD9强阳性表达的胃癌患者的总5年生存率显著低于NEDD9阴性和弱阳性表达组。NEDD9可作为临床中预测胃癌患者预后的生物标志物。
